← Human Trials & Peer-Reviewed Studies
Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease
Plain-language guide to PMID 11300448 (2001): double-blind randomized controlled trial of Endothelin-1 in 20 women.
Key Facts
- PMID
- 11300448
- Journal
- Journal of the American College of Cardiology
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Jhund PS et al. (7 authors)
- DOI
- 10.1016/s0735-1097(01)01168-8
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Endothelin-1, published as a randomized controlled trial.
The goal of this study was to determine the long-term effects of estrogen replacement therapy on the response to endothelin-1 (ET-1) in postmenopausal women with coronary heart disease.
Why It Was Studied
It is thought that the vasoconstrictor ET-1 is involved in the development and progression of atherosclerosis.
Estrogen replacement may slow the development of atherosclerosis in postmenopausal women.
Who Took Part
The study group was 20 women.
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.
Neither the women nor the staff measuring them knew who was on Endothelin-1, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Endothelin-1 group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Blood Flow Velocity, Coronary Disease, Endothelin-1, Estradiol, Estrogen Replacement Therapy, Forearm and Plethysmography.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Endothelin-1 in 20 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2001 (Journal of the American College of Cardiology), a journal based in United States.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.